Novel bis-ureido-substituted sulfaguanidines and sulfisoxazoles as carbonic anhydrase and acetylcholinesterase inhibitors

ArticleAçık Erişim

Özet

Abstract: To discover alternative substances to compounds used to treat many diseases, especially treating Alzheimer’s disease (AD) and Parkinson’s disease targeting carbonic anhydrase (hCA) and acetylcholinesterase (AChE) enzymes, is important. For this purpose, a series of novel bis-ureido-substituted sulfaguanidine (SG1–4) and sulfisoxazole (SO1–4) derivatives were synthesized, and their inhibitory capacities were screened against hCA isoenzymes (hCA I and II) and AChE. Possible binding mechanisms of inhibitors to the active site were elucidated by in silico studies, and the results were supported by in vitro results. Moreover, the percent radical scavenging capacities of the derivatives were also evaluated. The derivatives (SG1–4 and SO1–4) were more effective against hCAs compared to standard drug acetazolamide (KI values of 98.28–439.17 nM for hCA I and II, respectively) and exhibited the highest inhibition with the KIs in the ranges of 2.54 ± 0.50–41.02 ± 7.52 nM for hCA I, 11.20 ± 2.97–67.14 ± 13.58 nM for hCA II, and 257.60 ± 27.84–442.60 ± 52.13 nM for AChE. Also, compounds SG1 and SO1 also showed ABTS radical scavenging activity at the rate of 70% and 78%, respectively. These results will contribute to the literature for the rational design and synthesis of new potent and selective inhibitors targeting hCAs and AChE with multifunctional effects such as radical scavenging as well as inhibition. Graphical abstract: This study focused on the synthesis and inhibitory effects of bis-ureido-substituted sulfaguanidine (SG1–4) andsulfisoxazole (SO1–4) derivatives against human hCA I and II isoforms and AChE. In order to test synthesizedderivatives’ free radical scavenging potentials were the DPPH and ABTS assays. In silico studies elucidatedpossible binding mechanisms of inhibitors to the active site.[Figure not available: see fulltext.]. © 2022, The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/12170Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1007/s11030-022-10527-0Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorLolak, Nebih
dc.contributor.authorAkocak, Süleyman
dc.contributor.authorDurgun, Mustafa
dc.contributor.authorDuran, Hatice Esra
dc.contributor.authorNecip, Adem
dc.contributor.authorTürkeş, Cüneyt
dc.contributor.authorIşık, Mesut
dc.contributor.authorBeydemir, Şükrü
dc.date.accessioned2026-10-18T20:27:06.341357182Z
dc.date.available2026-10-18T20:27:06.341357182Z
dc.date.issued2023
dc.description.abstractAbstract: To discover alternative substances to compounds used to treat many diseases, especially treating Alzheimer’s disease (AD) and Parkinson’s disease targeting carbonic anhydrase (hCA) and acetylcholinesterase (AChE) enzymes, is important. For this purpose, a series of novel bis-ureido-substituted sulfaguanidine (SG1–4) and sulfisoxazole (SO1–4) derivatives were synthesized, and their inhibitory capacities were screened against hCA isoenzymes (hCA I and II) and AChE. Possible binding mechanisms of inhibitors to the active site were elucidated by in silico studies, and the results were supported by in vitro results. Moreover, the percent radical scavenging capacities of the derivatives were also evaluated. The derivatives (SG1–4 and SO1–4) were more effective against hCAs compared to standard drug acetazolamide (KI values of 98.28–439.17 nM for hCA I and II, respectively) and exhibited the highest inhibition with the KIs in the ranges of 2.54 ± 0.50–41.02 ± 7.52 nM for hCA I, 11.20 ± 2.97–67.14 ± 13.58 nM for hCA II, and 257.60 ± 27.84–442.60 ± 52.13 nM for AChE. Also, compounds SG1 and SO1 also showed ABTS radical scavenging activity at the rate of 70% and 78%, respectively. These results will contribute to the literature for the rational design and synthesis of new potent and selective inhibitors targeting hCAs and AChE with multifunctional effects such as radical scavenging as well as inhibition. Graphical abstract: This study focused on the synthesis and inhibitory effects of bis-ureido-substituted sulfaguanidine (SG1–4) andsulfisoxazole (SO1–4) derivatives against human hCA I and II isoforms and AChE. In order to test synthesizedderivatives’ free radical scavenging potentials were the DPPH and ABTS assays. In silico studies elucidatedpossible binding mechanisms of inhibitors to the active site.[Figure not available: see fulltext.]. © 2022, The Author(s), under exclusive licence to Springer Nature Switzerland AG.
dc.description.sponsorshipThis work was supported by the Research Fund of Anadolu University (Grant Number 2102S003).
dc.identifier.doi10.1007/s11030-022-10527-0
dc.identifier.endpage1749
dc.identifier.issn1381-1991
dc.identifier.issue4
dc.identifier.pmid36136229
dc.identifier.scopus2-s2.0-85138503512
dc.identifier.startpage1735
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/12170
dc.identifier.volume27
dc.language.isoen
dc.publisherInstitute for Ionics
dc.relation.ispartofMolecular Diversity
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAcetylcholinesterase
dc.subjectCarbonic anhydrase
dc.subjectMolecular docking
dc.subjectSulfaguanidine
dc.subjectSulfisoxazole
dc.subjectCarbonic Anhydrase I
dc.subjectCarbonic Anhydrase II
dc.subjectCarbonic Anhydrase Inhibitors
dc.subjectCarbonic Anhydrases
dc.subjectCholinesterase Inhibitors
dc.subjectHumans
dc.subjectMolecular Structure
dc.subjectStructure-Activity Relationship
dc.subjectbis ureido substituted sulfaguanidine derivative
dc.subjectcarbonate dehydratase inhibitor
dc.subjectcholinesterase inhibitor
dc.subjectsulfisoxazole derivative
dc.subjectunclassified drug
dc.subject2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid
dc.subjectcarbonate dehydratase
dc.subjectcarbonate dehydratase I
dc.subjectcarbonate dehydratase II
dc.subjectsulfafurazole
dc.subjectantioxidant activity
dc.subjectArticle
dc.subjectcomputer model
dc.subjectdrug determination
dc.subjectdrug protein binding
dc.subjectdrug structure
dc.subjectdrug synthesis
dc.titleNovel bis-ureido-substituted sulfaguanidines and sulfisoxazoles as carbonic anhydrase and acetylcholinesterase inhibitors
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus58
rdl.departmentDepartment of Biochemistry, Faculty of Pharmacy, Erzincan Binali Yıldırım University, 24002, Erzincan, Turkey. cuneyt.turkes@erzincan.edu.tr.
rdl.source.indexSCOPUS
rdl.source.indexPUBMED